Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson & Johnson (JNJ) is scheduled to report its second-quarter earnings on July 16, with analysts anticipating EPS of $2.68, a decrease from $2.82 year-over-year, alongside a projected revenue increase to $22.86 billion from $22.45 billion. The company recently submitted a supplemental new drug application to the FDA for CAPLYTA, targeting schizophrenia relapse prevention. JNJ shares closed up 0.9% at $157.69, while analyst ratings and price targets show a mixed outlook for the stock.

Analysis

Johnson & Johnson is approaching its second-quarter earnings release with a mixed financial outlook. Analysts forecast a top-line increase, with revenues projected at $22.86 billion, up from $22.45 billion in the prior-year period. However, this growth is contrasted by an expected decline in profitability, as earnings per share are anticipated to fall to $2.68 from $2.82 year-over-year, signaling potential margin pressure. On the operational front, the company has shown positive pipeline momentum with its recent supplemental new drug application to the FDA for CAPLYTA, aimed at preventing schizophrenia relapse. This backdrop of conflicting fundamental signals is mirrored in analyst sentiment, which lacks a clear consensus. Recent ratings include a downgrade to Market Perform from Leerink Partners with a $153 price target, alongside maintained Equal-Weight ratings from Morgan Stanley and Barclays, and a sustained Outperform from Raymond James with a $164 target. With the stock currently trading at $157.69, it is positioned within a wide and divergent range of analyst price targets, reflecting significant uncertainty ahead of the earnings report.

Key Decisions for Investors

• Investors should scrutinize the upcoming earnings report for details on profit margins and management's guidance to understand the drivers of the expected profitability compression.
• The wide dispersion in analyst ratings and price targets, from $153 to $171, indicates a lack of conviction and suggests potential volatility around the earnings release, warranting a cautious approach.
• Long-term investors should monitor for updates on the pharmaceutical pipeline, as the recent FDA submission for CAPLYTA represents a potential value catalyst independent of near-term quarterly performance.